Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
humanized anti-CD52 monoclonal antibody
- Development stage
- Phase 1
- Lead developer
- Lanzhou Institute of Biological Products
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
humanized anti-CD52 monoclonal antibody is a recombinant humanized IgG1 monoclonal antibody targeting CD52 (CAMPATH-1 antigen). Co-developed by Lanzhou Institute of Biological Products and Shanghai Taiyin Biotechnology, it is designed to treat various hematological malignancies by binding to CD52 on the surface of mature lymphocytes and inducing cell depletion via antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The drug is currently undergoing Phase 1 clinical evaluation in China for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL)—including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), prolymphocytic leukemia (PLL), peripheral T-cell lymphoma (PTCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL)—as well as previously untreated T-cell prolymphocytic leukemia (T-PLL).
- Other names
- recombinant humanized anti-CD52 monoclonal antibodyrecombinant humanized anti-CD52 monoclonal antibody injection重组人源化抗CD52单克隆抗体重组人源化抗CD52单克隆抗体注射液
02
Targets
C1Q (Complement C1q)CD52 (CD52 Antigen)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)
Beyond the preview
Go deeper on humanized anti-CD52 monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on humanized anti-CD52 monoclonal antibody.